{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "24832599",
  "DateCompleted": {
    "Year": "2014",
    "Month": "10",
    "Day": "21"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2014",
        "Month": "05",
        "Day": "15"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1038/cddis.2014.186"
    ],
    "Journal": {
      "ISSN": "2041-4889",
      "JournalIssue": {
        "Volume": "5",
        "Issue": "5",
        "PubDate": {
          "Year": "2014",
          "Month": "May",
          "Day": "15"
        }
      },
      "Title": "Cell death & disease",
      "ISOAbbreviation": "Cell Death Dis"
    },
    "ArticleTitle": "Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.",
    "Pagination": {
      "StartPage": "e1227",
      "MedlinePgn": "e1227"
    },
    "Abstract": {
      "AbstractText": [
        "The involvement of Axl kinase in non-small cell lung cancer's (NSCLC) acquired resistance to tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib has been identified recently, but the mechanism by which Axl contributes to TKI resistance is largely unknown. MicroRNAs (miRNAs) repress gene expression and their critical role in tumorigenesis has been implicated. To investigate the role of miRNAs in the Axl-mediated acquired gefitinib resistance, we examined the Axl-mediated miRNA changes in gefitinib-resistant lung cancers. A panel of Axl kinase-altered miRNAs was identified. In this study, we validate and report that miR-374a and miR-548b modulated by Axl have essential roles in cell cycle arrest, gefitinib-induced apoptosis, epithelial-to-mesenchymal transition, migration and tumorigenesis of gefitinib-resistant lung cancer cells in vitro and in vivo by targeting Wnt5a and CCNB1 genes, respectively. Of clinical significance, high expression of Axl and miR-374a and low expression of miR-548b are associated with poor disease-free survival postoperatively. These findings indicate that the modulation of specific miRNAs may provide a therapeutic target to treat or reverse gefitinib resistance in NSCLC with high expression of Axl in the future."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Respiratory Medicine, Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, China."
          }
        ],
        "LastName": "Wang",
        "ForeName": "Y",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "1] Yijishan Hospital, Wannan Medical College, Wuhu, China [2] School of Medicine, Jinan University, Guangzhou, China."
          }
        ],
        "LastName": "Xia",
        "ForeName": "H",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China."
          }
        ],
        "LastName": "Zhuang",
        "ForeName": "Z",
        "Initials": "Z"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Respiratory Medicine, Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, China."
          }
        ],
        "LastName": "Miao",
        "ForeName": "L",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China."
          }
        ],
        "LastName": "Chen",
        "ForeName": "X",
        "Initials": "X"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Respiratory Medicine, Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, China."
          }
        ],
        "LastName": "Cai",
        "ForeName": "H",
        "Initials": "H"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Cell Death Dis",
    "NlmUniqueID": "101524092"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "CCNB1 protein, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cyclin B1"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "MIRN374 microRNA 374, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "MIRN548 microRNA, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "MicroRNAs"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Protein Kinase Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Proto-Oncogene Proteins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Quinazolines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "WNT5A protein, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Wnt Proteins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Wnt-5a Protein"
    },
    {
      "RegistryNumber": "EC 2.7.10.1",
      "NameOfSubstance": "Receptor Protein-Tyrosine Kinases"
    },
    {
      "RegistryNumber": "S65743JHBS",
      "NameOfSubstance": "Gefitinib"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Axl Receptor Tyrosine Kinase"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Apoptosis"
    },
    {
      "QualifierName": [
        "drug therapy",
        "enzymology",
        "genetics",
        "mortality",
        "pathology"
      ],
      "DescriptorName": "Carcinoma, Non-Small-Cell Lung"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Cell Cycle Checkpoints"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cell Line, Tumor"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Cell Movement"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Cyclin B1"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease-Free Survival"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Dose-Response Relationship, Drug"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Resistance, Neoplasm"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Epithelial-Mesenchymal Transition"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Gefitinib"
    },
    {
      "QualifierName": [],
      "DescriptorName": "HEK293 Cells"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Kaplan-Meier Estimate"
    },
    {
      "QualifierName": [
        "drug therapy",
        "enzymology",
        "genetics",
        "mortality",
        "pathology"
      ],
      "DescriptorName": "Lung Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mice"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mice, Nude"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "MicroRNAs"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neoplasm Invasiveness"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Protein Kinase Inhibitors"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Proto-Oncogene Proteins"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Quinazolines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "RNA Interference"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Receptor Protein-Tyrosine Kinases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Transfection"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Tumor Burden"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Wnt Proteins"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Wnt-5a Protein"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Xenograft Model Antitumor Assays"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Axl Receptor Tyrosine Kinase"
    }
  ]
}